middle.news
OncoSil Medical Shows Promising Interim OSPREY Registry Results in Pancreatic Cancer
8:29pm on Friday 15th of May, 2026 AEST
•
Healthcare
Read Story
OncoSil Medical Shows Promising Interim OSPREY Registry Results in Pancreatic Cancer
8:29pm on Friday 15th of May, 2026 AEST
Key Points
No serious adverse device effects reported
Local disease control rates above 77%
Median overall survival exceeds 20 months
Seven patients downstaged to surgery with high R0 resection rate
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Oncosil Medical (ASX:OSL)
OPEN ARTICLE